EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial

Maximiliano Gelli iD, Jacques Ewald, Marie-Laure Tanguy iD, Guillaume Passot, Francois Quenet, Yann Touchefeu iD, Hélène Senellart, Fabrice Muscari, Astrid Lievre, René Adam, Lambros Tselikas, Thomas Aparicio iD und 9 weitere

Journal of Clinical Oncology · 20.05.2026 · 44 (15) · 1416-1429

DOI: 10.1200/jco-25-01737 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2026. Verfasst von Maximiliano Gelli und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia, Surgery and Interventional Radiology, Gustave Roussy Hospital, University of Paris-Saclay, Villejuif, France. Hauptthemen laut MEDLINE: Liver Neoplasms, Colorectal Neoplasms, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the efficacy and safety of adjuvant hepatic arterial infusion (HAI) of oxaliplatin combined with intravenous (IV) fluorouracil/leucovorin (LV5FU2) after curative-intent surgery of ≥4 colorectal liver metastases (CRLM). METHODS Patients with an Eastern Cooperative Oncology Group performance status 0-1, who underwent resection or ablation of ≥4 CRLM after preoperative IV chemotherapy were enrolled. Patients were randomly assigned (1:1) to receive adjuvant oxaliplatin via HAI (HAI group, n = 50) or IV infusion (IV group, n = 49), both combined with IV LV5FU2 for at least 3 months. The primary end point was hepatic recurrence-free survival (h-RFS). Secondary end points included RFS, overall survival (OS), safety, and feasibility. RESULTS After a median follow-up of 59 months (IQR, 45-71), the median h-RFS was 25 (95% CI, 16 to 37) months in the HAI group versus 12 (95% CI, 8 to 19) months in the IV group (hazard ratio [HR], 0.63 [95% CI, 0.40 to 0.99]; P = .047). Median RFS was 14 months (95% CI, 10 to 20) in the HAI group versus 9 months (95% CI, 7 to 11) in the IV group (HR, 0.63 [95% CI, 0.41 to 0.97]; P = .03). Median OS was 74 months (95% CI, 51 to not defined) in the HAI group versus 57 months (95% CI, 37 to 69) in the IV group (HR, 0.61 [95% CI, 0.33 to 1.12]; P = .11). Five-year OS was 62% in the HAI arm compared with 47% in the IV arm. Grade 3 to 4 adverse events occurred in 58% of HAI patients and 32% of IV patients ( P = .02). No treatment-related deaths were reported. Four or more cycles of adjuvant chemotherapy were delivered in 81% of patients in the HAI group and 78% in the IV group ( P = .75). CONCLUSION Adjuvant oxaliplatin HAI plus LV5FU2 improves h-RFS after curative-intent surgery of CRLM in high-risk patients, with an acceptable safety profile. These results support further evaluation in a phase III trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsColorectal NeoplasmsOxaliplatinAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedInfusions, Intra-ArterialFemaleMaleAgedHepatic ArteryFluorouracilChemotherapy, AdjuvantLeucovorinInfusions, Intravenous

Substanzen

OxaliplatinFluorouracilLeucovorin

Autor:innen und Institutionen

  • Department of Anaesthesia, Surgery and Interventional Radiology, Gustave Roussy Hospital, University of Paris-Saclay, Villejuif, France.
  • Department of Surgery, Paoli-Calmettes Institute, Marseille, France.
  • Department of Biostatistics and Epidemiology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.
  • Department of Surgical Oncology, University Hospital Lyon Sud, Pierre Bénite, France.
  • Department of Surgical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.

ORCID-Profile: Maximiliano Gelli, Marie-Laure Tanguy, Yann Touchefeu, Thomas Aparicio, Julien Taieb, David Tougeron, David Malka

Zitieren

APA

Gelli, M., Ewald, J., Tanguy, M. L., Passot, G., Quenet, F., Touchefeu, Y., Senellart, H., Muscari, F., Lievre, A., Adam, R., Tselikas, L., Aparicio, T., Taieb, J., Mastier, C., Regimbeau, J. M., Asnacios Lecerf, A., Tougeron, D., Boige, V., De Baere, T., …, & Goéré, D. (2026). Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Journal of Clinical Oncology, 44(15), 1416-1429. https://doi.org/10.1200/jco-25-01737

Vancouver

Gelli M, Ewald J, Tanguy ML, Passot G, Quenet F, Touchefeu Y, et al. Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Journal of Clinical Oncology. 2026;44(15):1416-1429. doi:10.1200/jco-25-01737

BibTeX
@article{Gelli2026,
  author = {Gelli, Maximiliano and Ewald, Jacques and Tanguy, Marie-Laure and Passot, Guillaume and Quenet, Francois and Touchefeu, Yann and Senellart, Hélène and Muscari, Fabrice and Lievre, Astrid and Adam, René and Tselikas, Lambros and Aparicio, Thomas and Taieb, Julien and Mastier, Charles and Regimbeau, Jean-Marc and Asnacios Lecerf, Amani and Tougeron, David and Boige, Valerie and De Baere, Thierry and Malka, David and Goéré, Diane},
  title = {Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {15},
  pages = {1416--1429},
  doi = {10.1200/jco-25-01737}
}
Kostenlos starten →